Research ArticleHuntington’s Disease
Huntingtin suppression restores cognitive function in a mouse model of Huntington’s disease
- Amber L. Southwell1,*,
- Holly B. Kordasiewicz2,
- Douglas Langbehn3,
- Niels H. Skotte1,†,
- Matthew P. Parsons4,‡,
- Erika B. Villanueva1,§,
- Nicholas S. Caron1,
- Michael E. Østergaard2,
- Lisa M. Anderson1,
- Yuanyun Xie1,
- Louisa Dal Cengio1,
- Hailey Findlay-Black1,
- Crystal N. Doty1,
- Bethany Fitsimmons2,
- Eric E. Swayze2,
- Punit P. Seth2,
- Lynn A. Raymond4,
- C. Frank Bennett2 and
- Michael R. Hayden1,¶
- 1Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada.
- 2Ionis Pharmaceuticals, Carlsbad, CA 92008, USA.
- 3Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
- 4Department of Psychiatry, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
- ↵¶Corresponding author. Email: mrh{at}cmmt.ubc.ca
↵* Present address: Burnett School of Biomedical Sciences, Division of Neuroscience, University of Central Florida, Orlando, FL 32827, USA.
↵† Present address: Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark.
↵‡ Present address: Faculty of Medicine, Division of Biomedical Sciences, Memorial University, St. John’s, Newfoundland A1C 5S7, Canada.
↵§ Present address: Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen 2200, Denmark.
See allHide authors and affiliations
Science Translational Medicine 03 Oct 2018:
Vol. 10, Issue 461, eaar3959
DOI: 10.1126/scitranslmed.aar3959
